scispace - formally typeset
E

Evelyne Jacqz-Aigrain

Researcher at Paris Diderot University

Publications -  335
Citations -  8711

Evelyne Jacqz-Aigrain is an academic researcher from Paris Diderot University. The author has contributed to research in topics: Population & Pharmacokinetics. The author has an hindex of 47, co-authored 324 publications receiving 7850 citations. Previous affiliations of Evelyne Jacqz-Aigrain include Paris Descartes University & Institute of Tropical Medicine Antwerp.

Papers
More filters
Journal ArticleDOI

Nomenclature for human CYP2D6 alleles.

TL;DR: It is proposed that alleles be designated by CYP2D6 followed by an asterisk and a combination of roman letters and arabic numerals distinct for each allele with the number specifying the key mutation and, where appropriate, a letter specifying additional mutations.
Journal ArticleDOI

Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units.

TL;DR: The purpose of this study was to determine the risk factors for sepsis, the causative organisms, and mortality following infection in a large and diverse sample of NICUs, and to conclude that overall mortality in VLBW infants with early- and late-onset sepsi is higher than in infants with negative cultures.
Journal ArticleDOI

Expression of CYP2D6 in developing human liver

TL;DR: The rise in CYP2D6 protein was associated with the developmental onset of dextromethorphan O-dem methylation, but not N-demethylation, even if activity was lower in fetal than in neonatal and in adult liver microsomes, suggesting that regulation is primarily at the transcriptional level, but cannot rule out the participation of post-transcriptional events in the regulation process throughout ontogenesis.
Journal ArticleDOI

Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.

TL;DR: The population pharmacokinetic–pharmacogenetic model developed in de novo pediatric kidney transplant patients demonstrated that, in children, tacrolimus dosage should be based on weight, hematocrit levels, and CYP3A5 polymorphism.
Journal ArticleDOI

Ciprofloxacin safety in paediatrics: a systematic review

TL;DR: Musculoskeletal AEs occur due to ciprofloxacin use, however, these musculoskletal events are reversible with management and it is recommended that further prospective controlled studies should be carried out to evaluate the safety of ciproskeletal events, with particular focus on the risk of arthropathy.